Filing Details
Aprea Therapeutics, Inc. (NASDAQ:APRE) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:APRE
Aprea Therapeutics, Inc. (APRE) Files Quarterly Report for Q0
Aprea Therapeutics, Inc. (NASDAQ:APRE) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 12, 2026.
At publication ·
What changed
Aprea Therapeutics, Inc. (NASDAQ:APRE) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Aprea Therapeutics filed its quarterly report (Form 10-Q) with the SEC on August 12, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $0.68 per share with a market capitalization of $6.4 million as of the filing date.
- The quarterly report includes updated risk factors and changes in business conditions since the last annual filing, though specific revenue figures and financial metrics are not disclosed in this summary.
Market Context
Aprea Therapeutics, Inc.'s stock currently trades at $0.68 with a market capitalization of $6.4M.
The 10-Q provides Aprea Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Aprea Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View APRE Stock Page
Frequently Asked Questions
Where can I read APRE's SEC filings?
Browse all filings on our APRE SEC filings page.
What types of SEC filings does Aprea Therapeutics, Inc. file?
Public companies like Aprea Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.